Abrdn Life Sciences Investors (HQL)

HQL Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Other Revenue	1.94	3.98	3.02	2.29	3.39
Revenue	1.94	3.98	3.02	2.29	3.39
Revenue Growth (YoY)	-51.30%	31.83%	32.05%	-32.59%	38.97%
Gross Profit	1.94	3.98	3.02	2.29	3.39
Selling, General & Admin	5.31	5.9	6.01	6.43	5.51
Operating Expenses	5.31	5.9	6.01	6.43	5.51
Operating Income	-3.37	-1.92	-2.99	-4.14	-2.11
Currency Exchange Gain (Loss)	-	-	0	-0.01	-0.01
Other Non Operating Income (Expenses)	0.85	0.69	1.75	2.08	0.48
EBT Excluding Unusual Items	-2.52	-1.23	-1.24	-2.06	-1.64
Gain (Loss) on Sale of Investments	88.11	86.53	-103.37	66.59	124.7
Pretax Income	85.59	85.3	-104.6	64.53	123.05
Net Income	85.59	85.3	-104.6	64.53	123.05
Net Income to Common	85.59	85.3	-104.6	64.53	123.05
Net Income Growth	0.35%	-	-	-47.56%	-
Shares Outstanding (Basic)	30	28	26	25	24
Shares Outstanding (Diluted)	30	28	26	25	24
Shares Change (YoY)	5.48%	9.28%	4.10%	3.29%	3.03%
EPS (Basic)	2.89	3.04	-4.07	2.62	5.15
EPS (Diluted)	2.89	3.04	-4.07	2.62	5.15
EPS Growth	-4.86%	-	-	-49.23%	-
Dividend Per Share	1.820	1.660	1.470	1.670	1.470
Dividend Growth	9.64%	12.93%	-11.98%	13.61%	-1.34%
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-174.11%	-48.25%	-99.05%	-181.04%	-62.35%
Profit Margin	4415.74%	2143.13%	-3464.88%	2822.50%	3628.14%
EBIT	-3.37	-1.92	-2.99	-4.14	-2.11
EBIT Margin	-174.11%	-48.25%	-99.05%	-181.04%	-62.35%
Revenue as Reported	1.94	3.98	3.02	2.29	3.39

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q